# Zydus Lifesciences Growth Strategy

> Zydus forecasts steady growth for five years as innovation matures.
- Title: Zydus Lifesciences Growth Strategy · The Economic Times
- Summary: Zydus forecasts steady growth for five years as innovation matures. Zydus Lifesciences expects decent revenue growth and improved profitability through…
- Keywords: zydus lifesciences, specialty medicines, complex biologics, saroglitazar, us launch, oncology, ebitda, Zydus, Lifesciences, Growth, Strategy, The Economic Times
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/zydus-lifesciences-expects-decent-growth-for-five-years-as-innovation-matures-sharvil-patel/articleshow/134444729.cms
- Author: Rica Bhattacharyya
- Published: 2026-09-23T18:45:00+00:00
- Read time: 1 min
- Topics: zydus lifesciences, specialty medicines, complex biologics, saroglitazar, us launch, oncology, ebitda
## Zydus Transition
Zydus shifts from traditional pharma to patient-driven model.
## Five-Year Growth
Zydus expects decent growth for next five years.
## US Market Focus
US generics remain largest market with room for growth.
## Saroglitazar Test
Saroglitazar aims for 18-20% US prescription share.
## Innovation Matures
Profitability improves as innovation matures by 2030.
## Oncology Expansion
Zydus leads global ADCs and precision diagnostics for cancer.
## Future Strategy
Zydus targets 24% Ebitda by 2030 with specialty focus.
## Key takeaway

Zydus Lifesciences expects decent revenue growth and improved profitability through specialty medicines and biologics by 2030.